Trial Profile

The Comparisons of the Efficacy and Safety of Inhaled LAMA or LAMA+LABA or ICS+LABA for Patients in COPD C Group With Bronchiectasis

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide/formoterol (Primary) ; Tiotropium bromide (Primary)
Indications Bronchiectasis; Chronic obstructive pulmonary disease
Focus Therapeutic Use

Most Recent Events

29 Jul 2019 Planned number of patients changed from 80 to 90.
29 Jul 2019 Planned End Date changed from 1 Mar 2017 to 1 Mar 2021.
29 Jul 2019 Planned primary completion date changed from 1 Dec 2016 to 15 Sep 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com